National

Covid vax could be ready by Dec, says SII; but adds 2 conditions

Covid vax could be ready by Dec, says SII; but adds 2 conditions
NEW DELHI, OCT 28 (AGENCIES) | Publish Date: 10/28/2020 12:49:10 PM IST

Covishield, a vaccine candidate that has shown promise during trials, may be ready by December 2020, Serum Institute of India CEO Adar Poonawalla told News18. He, however, added the caveat that “a lot is subject to data from the UK and also a lot depends on the approvals coming through from the Drugs Controller General Of India”.

What this means is that the company, which is developing Oxford University’s vaccine in India, intends to apply for emergency authorization if the data from the UK trials show promise.

The government of India, has in the past indicated that emergency authorization of a vaccine is likely if the need arises. The phase-III trials of Oxford University-AstraZeneca’s coronavirus vaccine candidate are currently underway in the UK.

Covishield, developed at the Jenner Institute of the Oxford University in the UK and licensed from Anglo Swedish drug maker AstraZeneca, is currently undergoing the final phase of clinical trials in India among nearly 1,600 people. Serum has floated a new company Serum Institute Life Sciences (SILS) that will exclusively focus on developing, producing and supplying pandemic vaccines.

On Tuesday, Poonawalla termed as “preliminary good news” an announcement by British drugmaker AstraZeneca that an experimental Covid-19 vaccine being developed by the University of Oxford is producing an immune response in both younger and older adults.

“A lot of people were wondering and asking the question, will these early vaccines be effective for the elderly and most vulnerable, here is some preliminary good news,” Poonwalla said on Twitter.

On September 26, Adar Poonawala had questioned whether the Government was willing to shell out around Rs 80,000 crore for the COVID-19 vaccine. 

In response, on September 30, Rajesh Bhushan disputed the costs calculated by Poonawala. Though he did not state the exact amount calculated by the Ministry, Bhushan said that the National Committee was mulling over the costs.

Serum Institute of India which is manufacturing the Oxford, AstraZeneca vaccine has been funded by the Bill and Melinda Gates Foundation to produce 200 million doses under this scheme.

 

Launched on December 3,1990. Nagaland Post is the first and highest circulated newspaper of Nagaland state. Nagaland Post is also the first newspaper in Nagaland to be published in multi-colour.

Desk:+91-3862-248 489, e-mail: npdesk@gmail.com Fax: +91-3862-248 500
Advt.:+91-3862-248 267, e-mail:npostadvt@gmail.com

QUICK LINKS

SUNDAY POST

Join us on

© Nagaland Post 2018. All Rights are Reserved
Designed by : 4C Plus